Uterine Carcinosarcoma

specific

An aggressive, high-grade malignant tumor that arises from the uterine corpus or cervix and is composed of carcinomatous and sarcomatous elements. The vast majority of cases are malignant mixed mesodermal (Mullerian) tumors that originate from the Mullerian ducts. Exceedingly rare cases that arise from mesonephric remnants have also been described.

61

Centers

13

Active Trials

Cancer Funding

Top Centers for Uterine Carcinosarcoma(61)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
High-Volume Research Center
73.0
2
NCI Comprehensive
Active Research Program
68.5
3
NCI Comprehensive
Active Research Program
68.5
4
NCI Comprehensive
Active Research Program
68.5
5
NCI Comprehensive
Active Research Program
68.5
6
NCI Comprehensive
Active Research Program
68.5
7
NCI Comprehensive
Active Research Program
68.5
8
Active Research Program
68.5
9
Active Research Program
68.5
10
Active Research Program
68.5
11
Active Research Program
68.5
12
Active Research Program
68.5
13
NCI Comprehensive
46.4
14
NCI Comprehensive
46.4
15
NCI Comprehensive
46.4
16
NCI Comprehensive
46.4
17
NCI Comprehensive
46.4
18
NCI Comprehensive
46.4
19
NCI Comprehensive
46.4
20
NCI Comprehensive
46.4
2146.4
2246.4
2346.4
24
NCI Comprehensive
46.4
2546.4
26
NCI Comprehensive
46.4
27
NCI Comprehensive
46.4
28
NCI Comprehensive
46.4
29
NCI Comprehensive
46.4
30
NCI Comprehensive
46.4
31
NCI Comprehensive
46.4
32
NCI Comprehensive
46.4
3346.4
3446.4
35
NCI Comprehensive
46.4
36
Cedars-Sinai CancerLos Angeles, CA
46.4
3746.4
38
NCI Comprehensive
46.4
3946.4
4046.4
41
NCI Comprehensive
46.4
42
NCI Comprehensive
46.4
43
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
46.4
4446.4
4546.4
46
Fox Chase Cancer CenterPhiladelphia, PA
NCI Comprehensive
46.4
47
NCI Comprehensive
46.4
4846.4
4946.4
5046.4
5146.4
5246.4
5346.4
5446.4
5546.4
5646.4
5746.4
5846.4
5946.4
60
BC CancerVancouver, BC
46.4
6146.4

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →